Literature DB >> 19913201

Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives.

Giovanni Addolorato1, Lorenzo Leggio, Silvia Cardone, Anna Ferrulli, Giovanni Gasbarrini.   

Abstract

Alcoholism and stress share some common neurobiological circuits, including the GABAergic system. In particular, the GABA(B) receptor seems to play an important role. The GABA(B) receptor agonist baclofen has been studied as a treatment for alcohol-dependent subjects. Baclofen administration in alcohol-dependent patients was able to promote abstinence, inducing the remission of withdrawal symptoms, reducing alcohol craving, and reducing alcohol intake. Baclofen also reduced anxiety in alcohol-dependent subjects, probably acting on brain stress circuitry and/or on other neuroendocrine systems. Baclofen also showed excellent safety and tolerability, even in alcohol-dependent patients with advanced liver disease (i.e., cirrhosis). Future studies should investigate which alcoholic subtype may better benefit of the administration of baclofen in the treatment of alcohol dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19913201     DOI: 10.1016/j.alcohol.2009.09.031

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  16 in total

Review 1.  Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Jane P Gagliardi
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  GABAB receptor-positive modulators: brain region-dependent effects.

Authors:  Julie G Hensler; Tushar Advani; Teresa F Burke; Kejun Cheng; Kenner C Rice; Wouter Koek
Journal:  J Pharmacol Exp Ther       Date:  2011-09-27       Impact factor: 4.030

3.  Effects of the GABAB receptor-positive modulators CGP7930 and rac-BHFF in baclofen- and γ-hydroxybutyrate-discriminating pigeons.

Authors:  Wouter Koek; Charles P France; Kejun Cheng; Kenner C Rice
Journal:  J Pharmacol Exp Ther       Date:  2012-02-07       Impact factor: 4.030

4.  GABAB receptor-positive modulators: enhancement of GABAB receptor agonist effects in vivo.

Authors:  Wouter Koek; Charles P France; Kejun Cheng; Kenner C Rice
Journal:  J Pharmacol Exp Ther       Date:  2010-07-13       Impact factor: 4.030

Review 5.  GABAergic contributions to alcohol responsivity during adolescence: insights from preclinical and clinical studies.

Authors:  Marisa M Silveri
Journal:  Pharmacol Ther       Date:  2014-03-11       Impact factor: 12.310

6.  Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats.

Authors:  Ajaykumar N Sharma; Ashish Pise; Jay N Sharma; Praveen Shukla
Journal:  Metab Brain Dis       Date:  2014-08-17       Impact factor: 3.584

7.  Discriminative stimulus effects of the GABAB receptor-positive modulator rac-BHFF: comparison with GABAB receptor agonists and drugs of abuse.

Authors:  Wouter Koek; Kejun Cheng; Kenner C Rice
Journal:  J Pharmacol Exp Ther       Date:  2012-12-28       Impact factor: 4.030

8.  GABBR1 and SLC6A1, Two Genes Involved in Modulation of GABA Synaptic Transmission, Influence Risk for Alcoholism: Results from Three Ethnically Diverse Populations.

Authors:  Mary-Anne Enoch; Colin A Hodgkinson; Pei-Hong Shen; Elena Gorodetsky; Cheryl A Marietta; Alec Roy; David Goldman
Journal:  Alcohol Clin Exp Res       Date:  2016-01       Impact factor: 3.455

9.  Relationship between the thyroid axis and alcohol craving.

Authors:  Elie G Aoun; Mary R Lee; Carolina L Haass-Koffler; Robert M Swift; Giovanni Addolorato; George A Kenna; Lorenzo Leggio
Journal:  Alcohol Alcohol       Date:  2014-11-28       Impact factor: 2.826

10.  The GABAB Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats.

Authors:  Eric Augier; Russell S Dulman; Ruslan Damadzic; Andrew Pilling; J Paul Hamilton; Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2017-03-15       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.